marivi-pazos-cvpk5Y4ZWUs-unsplash-1

In vivo – personalized

cancer therapies

In vivo cell reprogramming in AML and beyond

Modiblast pursues a novel in vivo cell reprogramming approach to treat hematological malignancies and other cancers. Our proprietary strategy aims to drive innate & adaptive immune responses and establish memory cells. With our lead pipeline program progressing towards a first clinical trial in acute myeloid leukemia (AML), we are in the process of raising our seed round. Our long-term vision is to establish a cancer backbone therapy capable of prolonging phases in remission. We aim to enable patients to self-administer this novel drug combination at home, drastically improving their quality of life.

Modiblast won the Startup Spotlight competition at the BIO-Europe 2022, was recognized as one of eight finalists of the 9th BioRiver Boost! Start-Up Competition 2022, and also ranked among the 20 Finalists of the WECONOMY Start-Up Competition 2022.

Increasing need for maintenance therapy

While progress has been made, still about 80% of all AML patients in remission relapse within 2 years. Only 30% survive more than 5 years after diagnosis. We aim to address the strong future need for remission-extending maintenance therapies.

Key benefits of our approach

Personalization

Triggers a personalized immune response against the tumor in vivo.

Logistics

Avoids known challenges limiting ex vivo cell- and gene therapies.

Quality of Life

Potential for a self-administrable formulation and once-daily dosing regimen.

Project Milestones and Outlook

Our first program, MB101, aims for fixed-dose combination of granulocyte-macro-phage colony stimulation factor (GM-CSF), and a „danger signal“, prostaglandin E1 (PGE1).

EU patent granted
The European patent EP 3217975 B1 is granted.
US patent granted
Our US patent “Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias” is issued under the number 10,912,820.
BfArM scientific advice and pre-CTA meeting
The decision paves the way for a swift transition into a first clinical trial once funding has been secured.
Fixed formulation
We aim to establish a fixed formulation for lead development program (GM-CSF + PGE1) suitable for self-application with a once-daily / twice-daily schedule.
IND/CTA
We aim to conduct a Phase 1/2 single-arm trial with approximately 75 AML patients.
March 11, 2020
February 9, 2021
Thursday, May 17, 2023
Next Steps
Next Steps

Fostering hematological recovery

Patient data hint at MB101’s ability to restore neutrophil and thrombocyte counts in heavily pre-treated patients, potentially avoiding neutropenia, thrombocytopenia, and the associated need for transfusions. A positive effect on hematological recovery could enable progressing into earlier lines of treatment or an expanded treatment label.

Latest Press Release

May 172023 

Modiblast MB101 program passes BfArM scientific advice and pre-CTA meeting without objections 

Modiblast announced that its lead development program MB101 has passed a recent scientific advice and pre-CTA meeting with the BfArM without objections. 
Learn more

Upcoming Events

Sep 25-262024 

24th Annual Biotech in Europe Forum

Meet Modiblast CEO Helga Schmetzer at Sachs Associates’ 24th Annual Biotech in Europe Forum in Basel.
Learn more